Connectivity-guided intermittent theta burst versus repetitive transcranial magnetic stimulation for treatment-resistant depression: a randomized controlled trial
- PMID: 38228914
- PMCID: PMC10878976
- DOI: 10.1038/s41591-023-02764-z
Connectivity-guided intermittent theta burst versus repetitive transcranial magnetic stimulation for treatment-resistant depression: a randomized controlled trial
Abstract
Disruption in reciprocal connectivity between the right anterior insula and the left dorsolateral prefrontal cortex is associated with depression and may be a target for neuromodulation. In a five-center, parallel, double-blind, randomized controlled trial we personalized resting-state functional magnetic resonance imaging neuronavigated connectivity-guided intermittent theta burst stimulation (cgiTBS) at a site based on effective connectivity from the right anterior insula to the left dorsolateral prefrontal cortex. We tested its efficacy in reducing the primary outcome depression symptoms measured by the GRID Hamilton Depression Rating Scale 17-item over 8, 16 and 26 weeks, compared with structural magnetic resonance imaging (MRI) neuronavigated repetitive transcranial magnetic stimulation (rTMS) delivered at the standard stimulation site (F3) in patients with 'treatment-resistant depression'. Participants were randomly assigned to 20 sessions over 4-6 weeks of either cgiTBS (n = 128) or rTMS (n = 127) with resting-state functional MRI at baseline and 16 weeks. Persistent decreases in depressive symptoms were seen over 26 weeks, with no differences between arms on the primary outcome GRID Hamilton Depression Rating Scale 17-item score (intention-to-treat adjusted mean, -0.31, 95% confidence interval (CI) -1.87, 1.24, P = 0.689). Two serious adverse events were possibly related to TMS (mania and psychosis). MRI-neuronavigated cgiTBS and rTMS were equally effective in patients with treatment-resistant depression over 26 weeks (trial registration no. ISRCTN19674644).
© 2024. The Author(s).
Conflict of interest statement
R.M. has received funding for research from Electromedical Products, Inc. and fees for participation in a Data Monitoring Ethics Committee for two trials in depression from Novartis plc. M.A. has received fees for consulting and giving lectures by Takeda Pharmaceutical, Janssen Pharmaceutical and the Clinical TMS Society. R.H.M.-W. declares fees for consulting and giving lectures from Janssen-Cilag, LivaNova, Lundbeck, P1Vital, Sage Therapeutics, Sothema and Takeda. No other potential conflicts of interest are reported for any of the other authors. No third parties have been involved in the study design, analysis and writing of the manuscript.
Figures
References
-
- National Institute for Health and Care Excellence. Depression in Adults: Treatment and Management. NICE Guidelines(NG222) (NICE, 2022). - PubMed
-
- Rush AJ, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am. J. Psychiatry. 2006;163:1905–1917. - PubMed
-
- Brunoni AR, et al. Repetitive transcranial magnetic stimulation for the acute treatment of major depressive episodes: a systematic review with network meta-analysis. JAMA Psychiatry. 2017;74:143–152. - PubMed
-
- Berlim MT, et al. Response, remission and drop-out rates following high-frequency repetitive transcranial magnetic stimulation (rTMS) for treating major depression: a systematic review and meta-analysis of randomized, double-blind and sham-controlled trials. Psychol. Med. 2014;44:225–239. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous
